Negotiation Skills for Rheumatologists
Physicians as a group are trained to have excellent clinical skills, but the difference between an average and extremely successful physician often comes down to factors outside of their ability to provide clinical care.
Read Article
ACR 2018 - Day 3 Report
Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included the PEXIVAS Study, ACR Reproductive Health Draft Guidelines, and a Proof of concept study
Read Article
The 16th Annual La Paulee
La Paulee is traditionally the party/feast after harvest and a time when hard work is rewarded with food, fun, and wine. And so it was that evening; after better understanding genes, cytokines, and pathology it was time to have a good time with friends, old and new.
Read Article
Update on Myositis
The ACR/ARHP 2018 national meeting in Chicago presented us with opportunities to learn more about inflammatory myositis. A particularly interesting lecture was HOT topics in myositis. There were a few abstracts on MDA-5 related disease and a few on new or repurposed medications for dermatomyositis which will be covered here.
Read Article
ACR 2018 - Day 1 Report
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Read Article
Rates of "indeterminate" results on quantiferon-IT assays were found to be significantly higher in systemic vasculitis (21%) than nonvasculitis pts and controls (7-7.5%). Indeterminate predictors were Syst vasculitis (OR 9.64), high NLR (OR 1.70). https://t.co/QqL2efsF7V
Dr. John Cush @RheumNow ( View Tweet)
Faculty Spotlight: Sherine Gabriel, MD, MSc is a rheumatologist, current president of Rush University, and Chief Academic Officer of @RushMedical will speak on the panel “How Far We Have Come” at the @WIMSummit- see her session Sept 21st! #WIMstrongertogether https://t.co/pdzXbUcHV9
Do your state have a pediatric rheumatologist? @ACRheum @ACRSimpleTasks #Act4Arthritis #rdam https://t.co/ZGvopF75lb
Nucala (mepolizumab) was approved in 2015 for severe eosinophilic asthma, and in 2017 for EGPA (Churg Strauss). The FDA has now approved it for use in Six to 11-Year-Old Children with Severe Eosinophilic Asthma https://t.co/orAaFCkR92
Dr. John Cush @RheumNow ( View Tweet)
Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc
Dr. John Cush @RheumNow ( View Tweet)
Metanalysis of 16 studyes Systemic Sclerosis pregnancies have a higher risk of miscarriages (OR 1.6), IUGR (OR 3.2), preterm births (OR 2.4) and low birth weight (OR 3.8). SSc pts have 2.8 fold higher rate of gestational HTN & 2.3x more C- sections. https://t.co/FuM0DZFR4k
Dr. John Cush @RheumNow ( View Tweet)
S.Sweden study of ANCA Assoc Vasculitis (GPA, MPA, EGPA) 195 pts followed x8 yrs: found all cancers increased (SIR=2.8). SIR for squamous cell CA=12.9; 4.3 bladder cancer, & 7.0 for pancreatic CA. CYC total <10g were not associated w/ higher CA https://t.co/wqRKaFYWGb
Dr. John Cush @RheumNow ( View Tweet)
Prospective ankylosing spondylitis cohort - 628 without HTN F/U x12 mos; 200 Rx w/ NSAIDs; of these 129 developed incident HTN. NSAID use associated with incr risk of HTN (HR 1.12; CI, 1.04‐1.20), not effected by age, biologics, dz activity https://t.co/T6y5OcCgMM
Links:
Dr. John Cush @RheumNow ( View Tweet)
Risk of HCQ/CQ Retinal toxicity was 5.5% in 326 SLE pts F/U x 12.8 yrs. None occured in 1st 5 yrs; earliest 8 yrs (max =33 years). Retinal toxicity cases tended to have more renal disease (22% vs 15%) and were slightly less likely to be Caucasian https://t.co/kSFVedbUPY
Dr. John Cush @RheumNow ( View Tweet)
90 SLE pts (SLEDAI<6) on immunosuppressives were given PBO or Live Virus zostavax - Vax pts had significantly higher Wk 6 anti-VZV IgG, more injection site reactions (31 vs 7%). 3 pts flared (1PBO; 2 Zostavax) and no one developed zoster postvaccination https://t.co/pVrQ4tHAwY
Dr. John Cush @RheumNow ( View Tweet)